Form 8-K Immuneering Corp For: May 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Pharma (TEVA) PT Raised to $18 at BofA Securities
May 9, 2024 6:16 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $18.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "We raise our TEVA PO to $18 (from $16) following positive Phase 3 SOLARIS trial
update for the Olanzapine LAI [long-acting... More
Immuneering Corporation (IMRX) PT Lowered to $1.50 at Jefferies
May 8, 2024 7:39 AM EDTJefferies analyst Michael Yee lowered the price target on Immuneering Corporation (NASDAQ: IMRX) to $1.50 (from $3.00) while maintaining a Hold rating.
The analyst comments "IMRX reported the Q with no surprises and reiterated key timelines for two data readouts coming in H2:... More
